RxDoctor Payments Data

Rimvida Obeleniene, MD

Cardiovascular Disease · Fairlawn, NJNPI 1073559597

Payments from drug & device makers

$573in general payments, 2019–2025

Across 12 payments — averaging $47.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$176
  • Boston Scientific$147
  • E.r. Squibb & Sons, L.L.C.$120
  • Novartis$54
  • Merck$22
  • Boehringer Ingelheim$15
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$55196%
  • Education$224%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$573 in reported general payments places this provider in the 20th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$345,059
Medicare patients
919
Services billed
4,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban527$561,085
EntrestoSacubitril/Valsartan169$254,600
JardianceEmpagliflozin165$202,527
Repatha SureclickEvolocumab120$124,719
XareltoRivaroxaban63$81,891
MultaqDronedarone Hcl50$57,958
BrilintaTicagrelor37$35,193
FarxigaDapagliflozin Propanediol26$30,103
VascepaIcosapent Ethyl72$28,861
Ranolazine ErRanolazine198$23,675
Praluent PenAlirocumab16$21,475
Metoprolol Succinate1,162$16,833
NexletolBempedoic Acid12$13,937
EdarbiAzilsartan Medoxomil29$13,929
Rosuvastatin Calcium774$13,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$54$254,600169 claims
Boehringer IngelheimJardiance$15$202,527165 claims
Esperion Therapeutics, Inc.Nexletol$15$13,93712 claims
Arbor Pharmaceuticals, Inc.Edarbi$13$13,92929 claims
MerckJanuvia$22$7,86412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Fairlawn

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →